# SPINK9

## Overview
SPINK9 is a gene that encodes the serine peptidase inhibitor Kazal type 9, a protein primarily involved in the regulation of protease activity within the skin. This protein, categorized as a serine protease inhibitor, is predominantly expressed in the epidermis, particularly in the palms and soles, where it plays a crucial role in maintaining skin barrier integrity and antimicrobial defense. The protein product, known as LEKTI-2, specifically inhibits kallikrein-related peptidase 5 (KLK5), a protease implicated in skin desquamation and inflammation. SPINK9's expression is upregulated in certain skin conditions, such as hyperkeratotic lesions, and it has been associated with various pathological states, including diabetes and cancer, suggesting its potential as a biomarker and therapeutic target (Liao2022SPINKs; MeyerHoffert2009Identification; Mussa2022Identification).

## Structure
SPINK9 encodes a peptide that functions as a specific inhibitor of kallikrein-related peptidase 5 (KLK5). The protein consists of 86 amino acids and includes a Kazal domain, which is a common feature among serine protease inhibitors. This domain is characterized by conserved tyrosine residues and disulfide bonds, which contribute to the stability of the protein's structure. The Kazal domain in SPINK9 shares structural similarities with other Kazal domains but is unique in its P1 residue, suggesting a distinct substrate binding mode (MeyerHoffert2009Identification).

SPINK9 is expressed in human skin, particularly in keratinocytes, and its expression increases during keratinocyte differentiation. The protein product, known as LEKTI-2, is localized in the stratum granulosum and stratum corneum of the skin, especially at palmar and plantar sites. LEKTI-2 specifically inhibits KLK5 but does not affect other serine proteases like KLK7 or trypsin (MeyerHoffert2009Identification). The expression of LEKTI-2 is upregulated in hyperkeratotic lesions, indicating a role in skin conditions characterized by excessive keratinization (MeyerHoffert2009Identification). The protein's inhibitory effect on KLK5 suggests it may influence various cancers, although its significance in tumor biology is not fully understood (Liao2022SPINKs).

## Function
SPINK9, a member of the serine protease inhibitor Kazal-type family, is primarily expressed in the epidermis of human palms and plays a significant role in maintaining skin barrier integrity. It functions as an epidermal antimicrobial peptide with the ability to selectively kill Escherichia coli, contributing to the skin's defense mechanisms (Liao2022SPINKs). SPINK9 exhibits a strong inhibitory effect on kallikrein-related peptidase 5 (KLK5) and a slight inhibitory effect on KLK8 at high concentrations, which are crucial for regulating protease activity in the skin (Liao2022SPINKs; MeyerHoffert2009Identification).

In addition to its antimicrobial properties, SPINK9 is involved in cellular processes such as keratinocyte migration. It activates purinergic receptors and promotes metalloproteinase/EGFR-dependent keratinocyte migration, which is essential for wound healing and skin regeneration (Liao2022SPINKs). The expression of SPINK9 in healthy palm and plantar skin, as well as in certain skin conditions like chronic simple lichens and actinic keratosis, underscores its role in maintaining epidermal homeostasis and potentially influencing tumor dynamics, although the latter's significance remains unclear (Liao2022SPINKs).

## Clinical Significance
SPINK9 has been identified as a gene with significant clinical implications, particularly in the context of diabetes and cancer. In type 1 diabetes mellitus (T1DM), SPINK9 is upregulated in patients with complications compared to those without, suggesting its potential as a biomarker for the development of T1DM complications. This altered expression indicates its involvement in the pathophysiology of T1DM, possibly through mechanisms related to peripheral insulin resistance and glucose intolerance (Mussa2022Identification). 

SPINK9 is also implicated in various skin conditions and cancers. It is strongly expressed in the epidermis of human palms and has been associated with conditions such as chronic simple lichens, actinic keratosis, and squamous cell carcinoma. Although the significance of its expression in squamous cell carcinoma remains unclear, SPINK9's role as an epidermal antimicrobial peptide and its inhibitory effect on KLK5, a protease associated with several cancers, suggest it could influence tumor progression (Liao2022SPINKs). 

The dysregulation of SPINK9 may contribute to inflammatory skin diseases, such as psoriasis, due to its role in skin barrier function and immune response modulation (Liao2022SPINKs).

## Interactions
SPINK9 is known to interact with kallikrein-related peptidases, particularly KLK5 and KLK8. It exhibits a strong inhibitory effect on KLK5 and a slight inhibitory effect on KLK8, but it may not inhibit other kallikreins (KLKs) (Liao2022SPINKs). SPINK9 is considered a better inhibitor of KLK5 than LEKTI under acidic conditions, which is relevant for its role in the skin barrier and antimicrobial defense (Liao2022SPINKs). 

SPINK9 also activates purinergic receptors, which are involved in various cellular processes, including cell migration. This activation promotes metalloproteinase/EGFR-dependent keratinocyte migration, indicating a role in skin repair and regeneration (Liao2022SPINKs). 

The expression of SPINK9 in various skin conditions, such as chronic simple lichens, actinic keratosis, and squamous cell carcinoma, suggests its involvement in skin pathology, although the significance of its expression in squamous cell carcinoma remains unclear (Liao2022SPINKs). Given its inhibitory effect on KLK5, which is associated with various cancers, SPINK9 is considered a potential tumor-influencing factor (Liao2022SPINKs).


## References


[1. (Liao2022SPINKs) Chengcheng Liao, Qian Wang, Jiaxing An, Minglin Zhang, Jie Chen, Xiaolan Li, Linlin Xiao, Jiajia Wang, Qian Long, Jianguo Liu, and Xiaoyan Guan. Spinks in tumors: potential therapeutic targets. Frontiers in Oncology, February 2022. URL: http://dx.doi.org/10.3389/fonc.2022.833741, doi:10.3389/fonc.2022.833741. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2022.833741)

[2. (MeyerHoffert2009Identification) Ulf Meyer-Hoffert, Zhihong Wu, and Jens-Michael Schr√∂der. Identification of lympho-epithelial kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor. PLoS ONE, 4(2):e4372, February 2009. URL: http://dx.doi.org/10.1371/journal.pone.0004372, doi:10.1371/journal.pone.0004372. This article has 56 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0004372)

[3. (Mussa2022Identification) Bashair M. Mussa, Thenmozhi Venkatachalam, Ankita Srivastava, Abeer Al-Habshi, Elamin Abdelgadir, Alaaeldin Bashier, Fatheya Al Awadi, Khadija Hafidh, Rifat Hamoudi, and Salah Abusnana. Identification of novel differentially expressed genes in type 1 diabetes mellitus complications using transcriptomic profiling of uae patients: a multicenter study. Scientific Reports, September 2022. URL: http://dx.doi.org/10.1038/s41598-022-18997-w, doi:10.1038/s41598-022-18997-w. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-022-18997-w)